Viking Therapeutics, Inc.
VKTXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company carries a $4.07B market cap, placing it firmly in the mid-cap category. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Market Cap
$4.07B
Beta
0.68
P/E (TTM)
—
P/E (Fwd)
-8.07
EPS (TTM)
$-4.67
EPS (Fwd)
$-4.32
ROE
-88.8%
ROA
-51.9%
Cash
$501.7M
Total Debt
$4.1M
Free CF
-$230.8M
52W Change
38.0%
Annual Financials
Cash vs Debt
Where VKTX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VKTX finished 1.24% above its 150-day moving average ($33.09) and 0.12% below its 200-day moving average ($33.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VKTX overbought or oversold?
At the September 3, 2026 close, VKTX's RSI(14) was 52.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $501.7M in cash and $4.1M in debt, VKTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$230.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -88.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.68 suggests VKTX is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing VKTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.